基于数字 PCR 的急性髓性白血病 GRHL2 甲基化检测：诊断、预后和监测。

IF 3 4区医学 Q2 GENETICS & HEREDITY

Epigenomics Pub Date : 2024-02-01 Epub Date: 2024-02-12 DOI:10.2217/epi-2023-0406

Jing Hua, Miaomiao Chu, Chaohui Wang, Hangfan Zhang, Jing Luan, Yifei Zhang, Qiang Li, Taiwu Xiao, Chuansheng Zhu, Xuan Li, Bo Fu

{"title":"基于数字 PCR 的急性髓性白血病 GRHL2 甲基化检测：诊断、预后和监测。","authors":"Jing Hua, Miaomiao Chu, Chaohui Wang, Hangfan Zhang, Jing Luan, Yifei Zhang, Qiang Li, Taiwu Xiao, Chuansheng Zhu, Xuan Li, Bo Fu","doi":"10.2217/epi-2023-0406","DOIUrl":null,"url":null,"abstract":"Background: Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene GRHL2 in AML has not been widely studied. Methods: Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect GRHL2 methylation levels to explore the value of GRHL2 methylation in the diagnosis, treatment response and prognosis of AML. Result: GRHL2 methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). GRHL2 methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). Conclusion: GRHL2 methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"233-247"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Digital PCR-based GRHL2 methylation testing in acute myeloid leukemia: diagnosis, prognosis and monitoring.\",\"authors\":\"Jing Hua, Miaomiao Chu, Chaohui Wang, Hangfan Zhang, Jing Luan, Yifei Zhang, Qiang Li, Taiwu Xiao, Chuansheng Zhu, Xuan Li, Bo Fu\",\"doi\":\"10.2217/epi-2023-0406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene GRHL2 in AML has not been widely studied. Methods: Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect GRHL2 methylation levels to explore the value of GRHL2 methylation in the diagnosis, treatment response and prognosis of AML. Result: GRHL2 methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). GRHL2 methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). Conclusion: GRHL2 methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.\",\"PeriodicalId\":11959,\"journal\":{\"name\":\"Epigenomics\",\"volume\":\" \",\"pages\":\"233-247\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epigenomics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2217/epi-2023-0406\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/12 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/epi-2023-0406","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

摘要

背景：急性髓性白血病（AML）是一种具有高复发率的挑战性疾病。癌症相关基因 GRHL2 在 AML 中的作用尚未得到广泛研究。研究方法收集了 73 名 AML 患者和 68 名健康对照者的外周血样本。采用液滴数字 PCR 检测 GRHL2 甲基化水平，以探讨 GRHL2 甲基化在急性髓细胞性白血病的诊断、治疗反应和预后中的价值。结果GRHL2甲基化在急性髓细胞性白血病患者中明显增加（p GRHL2甲基化与化疗反应相关（p 结论：GRHL2甲基化有望影响急性髓细胞性白血病的诊断、治疗反应和预后：GRHL2甲基化有望成为诊断急性髓细胞白血病患者和预测预后的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Digital PCR-based GRHL2 methylation testing in acute myeloid leukemia: diagnosis, prognosis and monitoring.

Background: Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene GRHL2 in AML has not been widely studied. Methods: Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect GRHL2 methylation levels to explore the value of GRHL2 methylation in the diagnosis, treatment response and prognosis of AML. Result: GRHL2 methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). GRHL2 methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). Conclusion: GRHL2 methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Epigenomics GENETICS & HEREDITY-

CiteScore

5.80

自引率

2.60%

发文量

审稿时长

>12 weeks

期刊介绍： Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community. Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.